Honeysuckle flower and application of active ingredients thereof in removing tobacco poison
By using honeysuckle and its active ingredients to reduce the nucleic acid damage to organisms by tobacco toxic compounds in smoking, the problem of difficulty in effectively reducing the harm of smoking to organisms in the prior art is solved, and the effect of significantly reducing the level of nucleic acid modification is achieved, and a new anti-smoking drug is provided.
Patent Information
- Application Number
- CN202510382111.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-03-28
- Publication Date
- 2025-06-20
AI Technical Summary
The prior art is difficult to effectively reduce the nucleic acid damage to organisms by tobacco toxic compounds in smoking, and traditional Chinese medicine theory lacks support for modern biochemical research and cannot be effectively applied in clinical practice.
Honeysuckle and its active ingredients such as chlorogenic acid, caffeic acid and luteolin are used to exert the efficacy by reducing the level of nucleic acid modification induced by tobacco exposure. LC-MS/MS was used to detect nucleic acid modification levels in rat lung tissues as a detection marker for tobacco exposure and tobacco drug intervention.
Honeysuckle and its active ingredients can effectively reduce the harm of toxic and harmful substances in smoking to organisms, significantly reduce the level of nucleic acid modification induced by smoking exposure, and provide a new anti-smoking drug with safety and easy-to-acceptance characteristics.
Smart Images
Figure CN120168536A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biological medicine technology, and particularly to the application of honeysuckle and its active ingredients in relieving tobacco toxicity. Experiments have proved that honeysuckle and its active ingredients can effectively reduce the nucleic acid damage of tobacco toxic compounds to organisms. Background Art
[0002] The harms of smoking cannot be underestimated. Tobacco contains a variety of toxic components, which greatly increase the risk of suffering from major diseases such as lung cancer and chronic obstructive pulmonary disease. These diseases caused by smoking generally show the characteristics of high morbidity and poor treatment effects, and most of them are chronic diseases with hidden symptoms in the early stage and are difficult to detect. Long-term smoking can cause irreversible damage to various organs of the human body, seriously threatening life and health. Therefore, timely intervention in the early stage of the disease can effectively reduce the disease risk and protect life and health.
[0003] In order to reduce the toxic effects of smoking, people have studied various smoking cessation products and methods. Currently popular products include various combined preparations of drinks, tablets, pills, etc. for clearing the lungs and relieving tobacco and alcohol toxicity, as well as various smoking cessation and detoxification methods including acupuncture therapy for smoking cessation and adding filters to cigarettes. However, these smoking cessation products and methods cannot effectively make most people adhere to use, and some drugs also have side effects and cannot be used as effective tobacco toxicity-relieving drugs for a long time. Electronic cigarettes, known as tar-free, have been proven to contain a large amount of other carcinogens and are also harmful.
[0004] Regarding the main toxic substances in tobacco, such as benzo[a]pyrene and acrolein, a large number of studies at home and abroad have proved the relationship between their chemical structures and physiological effects, so as to infer their pathogenic mechanisms and screen therapeutic drugs. However, the compounds contained in tobacco are very complex, and some of them are unproven unknown substances with complex interaction relationships in organisms. Analyzing only single or a few tobacco toxic components is difficult to comprehensively and synthetically reflect the overall exposure toxicity of smoking and the therapeutic effects of tobacco toxicity-relieving drugs. People understand the pathogenic factors of "tobacco toxicity" from the perspective of traditional Chinese medicine and introduce prescriptions for relieving tobacco toxicity, aiming to solve the overall biological toxicity induced by tobacco exposure. However, some traditional Chinese medicine theories still lack the support of modern biochemistry research, lack effective biomarkers for monitoring tobacco exposure and drug treatment, and the potential toxic side effects of unknown compounds have not been proven and cannot be further applied clinically. Therefore, using modern chemical detection technology and effective biological detection biomarkers is crucial in promoting the clinical application of traditional Chinese medicine.
[0005] Different from the analysis method using a single metabolite as a biomarker, toxic compounds in tobacco, such as nicotine, polycyclic aromatic hydrocarbons, formaldehyde, etc., can induce nucleic acid damage modifications in organisms. Nucleic acid modifications are closely related to the occurrence and development of a series of major diseases and can directly reflect the genotoxic effects of tobacco compounds. A large number of studies have shown that compared with non-smokers, the levels of nucleic acid damage modifications have shown significant changes in patients with various smoking-related diseases, which makes nucleic acid modifications a potential biomarker for tobacco toxin exposure. Summary of the Invention
[0006] Aiming at the problems existing in the prior art, the object of the present invention is to provide the application of honeysuckle and its active ingredients in the preparation of drugs for relieving tobacco toxins. The object of the present invention is to overcome many defects in the prior art, using nucleic acid modification as a detection biomarker, to provide the application of honeysuckle and its active ingredients in the preparation of drugs for relieving tobacco toxins. Using LC-MS / MS to detect nucleic acid modifications in rat lung tissues and taking it as a detection biomarker for tobacco exposure and the intervention of drugs for relieving tobacco toxins, comparing the changes in the group of nucleic acid damage pharmacodynamic markers in tissues before and after the administration of honeysuckle and its active ingredients, it is found that honeysuckle and chlorogenic acid, caffeic acid and luteolin in honeysuckle have good effects on relieving tobacco toxins. That is, after administering drugs for relieving tobacco toxins prepared from honeysuckle and chlorogenic acid, caffeic acid and luteolin, it can effectively reduce the harm of toxic and harmful substances in smoking to organisms.
[0007] In order to achieve the above-mentioned invention object, the present invention provides the following technical solutions.
[0008] The present invention discloses the application of honeysuckle or its extract in the preparation of drugs for relieving tobacco toxins.
[0009] Further, the drug for relieving tobacco toxins exerts its pharmacodynamic effect by reducing the level of nucleic acid modifications induced by tobacco exposure.
[0010] Furthermore, the nucleic acid modifications include at least one of 5-HMdC, N 2 -CMdG, 5-FdC, 8-oxo-dG and CrotondG.
[0011] Further, the honeysuckle extract contains at least one active ingredient of chlorogenic acid, caffeic acid and luteolin.
[0012] The present invention also discloses a screening method for drugs for relieving tobacco toxins, which is characterized in that nucleic acid modifications induced by tobacco toxic compounds are used as detection biomarkers, and the regulatory effect of candidate drugs on the level of nucleic acid modifications is quantitatively analyzed by LC-MS / MS.
[0013] Further, the nucleic acid modification biomarker is selected from at least one of 5-HMdC, N 2-CMdG, 5-FdC, 8-oxo-dG, or CrotondG and combinations thereof.
[0014] The present invention also discloses a drug composition for relieving tobacco toxicity, which is characterized by comprising honeysuckle extract and pharmaceutically acceptable excipients, wherein the content of chlorogenic acid in the honeysuckle extract is not less than 1.5%, the content of caffeic acid is not less than 1%, and the content of luteolin is not less than 0.05%.
[0015] Further, its dosage form is a pharmaceutically acceptable dosage form.
[0016] The present invention also discloses a method for detecting tobacco exposure, which is characterized by detecting the contents of 5-HMdC, N 2 -CMdG, 5-FdC, 8-oxo-dG, and CrotondG in a biological sample by LC-MS / MS, and using the level change as a biomarker for tobacco exposure.
[0017] Compared with the prior art, the beneficial effects of the present invention are as follows.
[0018] The present invention first proposes the application of honeysuckle and its active ingredients in drugs for relieving tobacco toxicity. Current research on relieving tobacco toxicity mostly focuses on single components in tobacco, ignoring the metabolism and interaction relationships of complex compounds in tobacco in the body. Traditional Chinese medicine treatment reduces the toxicity of tobacco from the overall perspective of organisms. However, smoking cessation and detoxification preparations based on traditional Chinese medicine theory lack effective exposure and treatment biomarkers and cannot be effectively applied clinically. Therefore, we used high-performance liquid chromatography tandem mass spectrometry (LC-MS / MS), combined with metabolite quantification, and determined a new traditional Chinese medicine for relieving tobacco toxicity - honeysuckle through reliable biomarkers, and found that its active ingredients chlorogenic acid, caffeic acid, and luteolin also have the effect of relieving tobacco toxicity.
[0019] Compared with existing smoking cessation and detoxification methods, honeysuckle comes from plants that are both medicine and food, does not contain high-dose toxic compounds, has a low price, and is more easily accepted by people. It is convenient for smokers to use, and can effectively reduce the harm of toxic and harmful substances in tobacco to smokers after taking.
[0020] The present invention first proposes a method for screening traditional Chinese medicines for relieving tobacco toxicity using nucleic acid modification as a detection biomarker. The present invention uses nucleic acid modification induced by toxic compounds in tobacco as a biomarker, first proves that nucleic acid modification is an effective biomarker for tobacco exposure, showing significant differences before and after smoking, uses it as an exposure and treatment biomarker, and then proves the application of honeysuckle in reducing the level change of nucleic acid modification induced by smoking exposure, indicating that honeysuckle has a good effect of relieving tobacco toxicity.
[0021] Compared with the markers related to tobacco toxic compound metabolites, nucleic acid modification is related to biological function regulation. The damaging modification of nucleic acids by smoking can induce a series of major diseases. Therefore, the screening of anti-smoking drugs using nucleic acid modification as a marker provides another dimension for clinical medication. In addition, different from existing clinical traditional Chinese medicines, the research of the present invention at the level of nucleic acid modification is conducive to drugs targeting tobacco toxins, and can maximize the exploration of the anti-smoking medicinal value of honeysuckle and its active ingredients. Description of the Drawings
[0022] Figure 1 Structural diagrams of nucleic acid modification reference standards and internal standard compounds for the detection of tobacco exposure markers.
[0023] Figure 2 Chromatogram of nucleic acid modification reference standards for the detection of tobacco exposure markers.
[0024] Figure 3 Nucleic acid modification markers detected in rat lung tissue samples.
[0025] Figure 4 To detect the nucleic acid modification levels in the lung tissues of the control group and the smoking exposure group.
[0026] Figure 5 To detect the nucleic acid modification levels in the lung tissues of the smoking exposure group and the honeysuckle administration group.
[0027] Figure 6 Extracted ion chromatograms detected by mass spectrometry of chlorogenic acid, caffeic acid, and luteolin in the honeysuckle extract.
[0028] Figure 7 Comparison of nucleic acid modification levels in the lung tissues before and after the administration of chlorogenic acid in the blank control group.
[0029] Figure 8 Comparison of nucleic acid modification levels in the lung tissues before and after the administration of caffeic acid in the blank control group.
[0030] Figure 9 Comparison of nucleic acid modification levels in the lung tissues before and after the administration of luteolin in the blank control group. Detailed Description of the Invention
[0031] The present invention will be further described in detail below with specific examples. However, this should not be construed as limiting the scope of the above subject matter of the present invention to the following examples. All technologies implemented based on the content of the present invention belong to the scope of the present invention.
[0032] Unless otherwise specified, the reagents and materials used in the present invention are all commercially available.
[0033] I. Methods and Materials.
[0034] 1. Main Reagents.
[0035] LC-MS grade acetonitrile, methanol, and ethanol were purchased from Merck (Darmstadt, Germany), HPLC grade formic acid was purchased from Shanghai Macklin Biochemical Co., Ltd. (Shanghai, China), and ultrapure deionized water was purified using a Milli-Q ultrapure water integrated system (Millipore, Bedford, MA, USA). Flos Lonicerae was purchased from Leyonshan Pharmaceutical Group Co., Ltd., and standards and internal standards were all purchased from Shanghai Macklin Biochemical Co., Ltd. (Shanghai, China). Chlorogenic acid, caffeic acid, and luteolin (BR, purity 98%) were purchased from Shanghai Macklin Biochemical Co., Ltd. (Shanghai, China).
[0036] 2. Preparation of Flos Lonicerae decoction.
[0037] The gastric lavage solution of Flos Lonicerae was prepared by boiling method. Weigh 75 g of Flos Lonicerae, add 12 times the amount of water, and soak for 30 minutes. Then bring to a boil over high heat and keep the water simmering gently over low heat for 30 minutes, and filter while it is hot. Add 10 times the amount of water to the filter residue and decoct again, keep the water simmering gently over low heat for 20 minutes, and filter while it is hot. Combine the filtrates and concentrate under reduced pressure to a concentration of 1 g / mL. (The reference is Zang Z et al. J Ethnopharmacol. doi:10.1016 / j.jep.2024.117776).
[0038] 3. Establishment of animal model.
[0039] An SD rat model of smoke exposure was established. Twenty-four SPF-grade male healthy SD rats at 8 weeks of age with an average body weight of 200 ± 20 g were selected. After 1 week of adaptive feeding, they were randomly divided into 6 groups with 4 rats in each group, namely the control group, the model group, the Flos Lonicerae administration group, the chlorogenic acid administration group, the caffeic acid administration group, and the luteolin administration group. The control group was exposed under blank control, and the model group and the administration groups used a professional smoking machine to simulate human smoking to generate smoke, and Diamond brand (Hard Special) cigarettes (Hebei, China, flue-cured type, tar content 11 mg, carbon monoxide content 13 mg) were used to actively expose the rats. The administration dose was 20 cigarettes per day (the reference for smoke exposure is Qin et al. Respiratory Research https: / / doi.org / 10.1186 / s12931-022-02070-1). They were exposed for 1 h each in the morning and afternoon, 7 days a week, for 8 weeks. The symptoms of the rats such as increased body temperature, red tongue, dry feces and skin, and excessive thirst and drinking proved that the model was successfully established.
[0040] In the honeysuckle administration group, administration was carried out after daily smoking exposure. According to the 2020 edition of the Pharmacopoeia of the People's Republic of China, the honeysuckle decoction with a dose of 900 mg / kg was used to intragastrically administer the smoked rats once a day. The control group only breathed fresh air.
[0041] In the groups administered with the active ingredients of honeysuckle, chlorogenic acid, caffeic acid, and luteolin, according to the 2020 edition of the Pharmacopoeia of the People's Republic of China, the content of chlorogenic acid should not be less than 1.5%. Combining with the pharmacokinetic studies of chlorogenic acid, caffeic acid, and luteolin in rats in the literature ([1] Li Jiarui, et al. Study on the protective effect of chlorogenic acid on PM2.5-induced lung injury in rats [J]. Journal of Toxicology, 2021, 35(06): 470-473+484. [2] Chen Xiujie, et al. Pharmacokinetic study of luteolin in rats [J]. Chinese Journal of Pharmaceutical Analysis, 2009, 29(09): 1462-1465.), according to the conversion of the active ingredients in 900 mg / kg of honeysuckle, the administration doses of the three compounds were determined to be 40 mg / kg. Therefore, chlorogenic acid, caffeic acid, and luteolin were intragastrically administered at a dose of 40 mg / kg respectively.
[0042] 4. Sample preparation (Reference: Guilbaud, A. et al. Nucleic Acids Res. 2023, 51(20): 10829-10845.).
[0043] (1) Obtain rat lung tissue samples from each group and store them at -80 °C.
[0044] (2) Use a DNA extraction kit (Tiangen Biochemical Technology Co., Ltd. Blood / Cell / Tissue Genomic DNA Extraction Kit (DP304), and the extraction steps refer to the operation manual) to extract DNA from the lung tissue, and add 5 μg / mL coformycin, 50 μg / mL tetrahydrouridine (THU), 100 μM desferrioxamine, and 100 μM butylated hydroxytoluene (BHT) to reduce oxidative loss.
[0045] (3) Quantify the extracted DNA using a 260 nm spectrophotometer.
[0046] (4) Take 30 μg of DNA for vacuum concentration and redissolve it with 90 μL of Tris-HCl (10 mM, PH = 8) buffer solution. The reconstituted solution contains 1 mM MgCl2, 10 μg / mL coformycin, 50 μg / mL THU, 1 mM desferrioxamine, and 1 mM BHT.
[0047] (5) Digest with 10 U benzonase, 5 U DNAse I, 17 U alkaline phosphatase and 0.1 U phosphodiesterase I. Add internal standard reagents gemcitabine and BZ-dA (final concentration 0.1 pmol / μL). Digest overnight at 37 °C.
[0048] (6) Add 500 μL of cold ethanol to terminate the reaction and precipitate proteins, and centrifuge at 12000 rpm for 10 min.
[0049] (7) Take the supernatant and concentrate it under vacuum, redissolve it in 100 μL of 10% methanol-aqueous solution, centrifuge at 12000 rpm for 10 min, and take the supernatant and transfer it to a liquid phase vial for LC-MS / MS analysis.
[0050] 5. LC-MS / MS detection.
[0051] LC-MS / MS system: Waters ACQUITY UPLC system (Waters Corp., Milford, MA, USA) in tandem with a triple quadrupole mass spectrometer Xevo TQ-XS (Waters Corp., Manchester, UK).
[0052] (1) Mobile phase A is 0.1% formic acid-acetonitrile, and mobile phase B is 0.1% formic acid-aqueous solution.
[0053] (2) Gradient elution is adopted, and the elution method is as follows: 0 - 2 min, 0% A; 2 - 14 min, 0 - 5% A; 14 - 24 min, 5 - 18% A; 24 - 25 min, 18 - 20% A; 25 - 28 min, 20 - 95% A; 28 - 32 min, 95% A; 32 - 33 min, 95 - 0% A; 33 - 40 min, 0% A. The flow rate is 0.2 ml / min.
[0054] (3) The length of the chromatographic column is 100 mm, the inner diameter of the chromatographic column is 2.1 mm, the particle size of the packing is 3 μm, model: Luna ® Omega 3μm Polar C18 100A. The temperature of the chromatographic column is set at 30 °C during detection.
[0055] (4) The mass spectrometry conditions are: positive ion scanning mode, adopt the MRM mode, the capillary voltage is 3.3 KV, the desolvation gas temperature is 550 °C, the spray voltage is 7.0 bar, and the collision energy is 10 eV.
[0056] The present invention detects 5 nucleic acid modifications in tissue samples, including 5-HMdC, N 2 -CMdG, 5-FdC, 8-oxo-dG, CrotondG, as detection markers for tobacco exposure and drug administration.
[0057] 6. Relative quantitative analysis.
[0058] In the LC-MS / MS system described above, 3 μg of DNA was injected into each lung tissue sample of the present invention, and the UV signal of dG was used to normalize the concentration of the tissue DNA sample.
[0059] The matrix effect was corrected by internal standard. The correction formula for the matrix effect is: PA adjusted by ME = PAsample / (ISTD PAsample / ISTD PAblank). (Note: PA is the abbreviation of peak area.) PAsample is the chromatographic peak area of the marker in the lung tissue sample; ISTD PAsample is the chromatographic peak area of the internal standard added to the lung tissue sample; ISTDPAblanke is the chromatographic peak area of the internal standard with 10% methanol-water as the matrix, and the final concentration of the internal standard is 0.1 pmol / μL. The injection volume is kept consistent. Among them, gemcitabine is used to correct the compounds with a retention time of 0 - 12 min, and BZ-dA is used to correct the compounds with a retention time after 12 min.
[0060] Table 1 Detection conditions of 5 tobacco exposure markers and internal standards during mass spectrometry detection 。
[0061] II. Experimental results.
[0062] 1. Identification of nucleic acid modifications in lung tissue using standards.
[0063] The present invention first selected 5 typical nucleic acid modifications related to tobacco exposure as markers, and used 2 nucleoside structural analogs as internal standards to avoid interference from endogenous compounds ( Figure 1 are the chemical structures of the standard and internal standard compounds), which were used to evaluate tobacco exposure and the effect of Lonicera japonica administration. The experimental results fully demonstrated that Lonicera japonica and chlorogenic acid, caffeic acid, and luteolin in Lonicera japonica have the effect of relieving tobacco toxicity.
[0064] In order to identify the nucleic acid modification signals in lung tissue, nucleic acid modification standards were analyzed by LC-MS / MS, aiming to correlate the retention time and MS / MS channels of the standards with the nucleic acid modification data in rat lung tissue ( Figure 2 ).
[0065] It can be seen from the LC-MS / MS results that the target nucleic acid modification can be detected from the lung tissues of rats using this method ( Figure 3 ).
[0066] 2. Cigarette smoke exposure induces an increase in the level of nucleic acid modification.
[0067] The present invention analyzed the content of nucleic acid modification in the lung tissues of rats with and without tobacco exposure. Using the relative quantitative analysis method, the two groups of data were compared, and it can be seen from the results that the difference in the level of nucleic acid modification between the smoking group and the non-smoking group is significant ( Figure 4 ). It shows that tobacco exposure can induce an increase in the level of nucleic acid modification in the lung tissues of rats, and nucleic acid modification can be used as a detection marker for tobacco exposure and subsequent treatment of cigarette smoke toxicity. Among them, *, P<0.05; **, P<0.01; ***, P<0.001; ns, no significance.
[0068] 3. Administration of honeysuckle can reduce the toxicity of cigarette smoke exposure.
[0069] Nucleic acid damage modification can directly reflect the genotoxic effect of tobacco components on organisms. Based on the above results, nucleic acid modification can be used as a detection marker for cigarette smoke exposure. Therefore, the present invention evaluated the effect of honeysuckle administration on cigarette smoke exposure based on the change in the level of nucleic acid modification. After administration of honeysuckle, compared with the smoking without drug group, there was an obvious decrease in the level of nucleic acid modification ( Figure 5 ). Among them, the levels of the typical marker of DNA oxidative damage 8-oxo-dG and the marker of lipid peroxidation CrotondG decreased significantly, verifying the anti-inflammatory and antioxidant effects of honeysuckle. It shows that honeysuckle can be used as an anti-cigarette smoke drug to reduce the up-regulation of nucleic acid modification level induced by tobacco exposure.
[0070] 4. Administration of chlorogenic acid in honeysuckle can reduce the toxicity of cigarette smoke exposure.
[0071] The main components of honeysuckle include chlorogenic acid, caffeic acid, luteolin, etc. The honeysuckle decoction was diluted 100 times with water and detected by LC-MS / MS. The extracted ion current chromatograms of chlorogenic acid, caffeic acid and luteolin are as Figure 6 shown, and all three components can be detected in the honeysuckle decoction.
[0072] Compared with the blank control group, the level of nucleic acid modification in the lung tissues of rats in the smoking group was significantly increased, while compared with the smoking without drug group, the level of nucleic acid modification in the lung tissues of rats in the chlorogenic acid administration group was significantly decreased ( Figure 7 ), indicating that chlorogenic acid can reduce the up-regulation of nucleic acid modification level induced by cigarette smoke exposure and can be used as an anti-cigarette smoke drug to intervene in the toxicity of smoking on organisms.
[0073] 5. Administration of caffeic acid in Lonicera japonica can reduce the toxicity of smoking exposure.
[0074] Compared with the blank control group, the nucleic acid modification level in the lung tissue of rats in the smoking group was significantly increased. However, compared with the smoking group without drug administration, the nucleic acid modification level in the lung tissue of rats in the caffeic acid administration group was significantly decreased ( Figure 8 ), indicating that caffeic acid can reduce the up-regulation of nucleic acid modification level induced by smoking exposure and can be used as an anti-smoking-toxicity drug to intervene in the toxic effect of smoking on organisms.
[0075] 6. Administration of luteolin in Lonicera japonica can reduce the toxicity of smoking exposure.
[0076] Compared with the blank control group, the nucleic acid modification level in the lung tissue of rats in the smoking group was significantly increased. However, compared with the smoking group without drug administration, the nucleic acid modification level in the lung tissue of rats in the caffeic acid administration group was significantly decreased ( Figure 9 ), indicating that caffeic acid can reduce the up-regulation of nucleic acid modification level induced by smoking exposure and can be used as an anti-smoking-toxicity drug to intervene in the toxic effect of smoking on organisms.
[0077] Conclusion: Compared with the control group, the nucleic acid modification level in the lung tissue of rats exposed to tobacco was increased, while the nucleic acid modification level in the lung tissue of rats after administration of Lonicera japonica was significantly decreased, indicating that Lonicera japonica can be used as a traditional Chinese medicine to reduce the change of nucleic acid modification level induced by smoking-toxicity exposure. And the active components of Lonicera japonica, chlorogenic acid, caffeic acid and luteolin, can also reduce the change of nucleic acid modification level induced by smoking exposure. The above shows that Lonicera japonica and its components chlorogenic acid, caffeic acid and luteolin can be used as effective anti-smoking-toxicity drugs.
[0078] The above are only the preferred embodiments of the present invention and are not used to limit the patent scope of the present invention. For those skilled in the art, various changes and modifications can be made to the present invention. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. Use of honeysuckle or its extract in preparing a drug for detoxifying tobacco.
2. The use according to claim 1, characterized in that: The antidote for tobacco poisoning exerts its efficacy by reducing the level of nucleic acid modification induced by tobacco exposure.
3. The use according to claim 2, characterized in that: The nucleic acid modification includes 5-HMdC, N 2 -At least one of CMdG, 5-FdC, 8-oxo-dG and CrotondG.
4. The use according to claim 1, characterized in that: The honeysuckle extract contains at least one active ingredient of chlorogenic acid, caffeic acid and luteolin.
5. A method for screening a drug for detoxifying tobacco, characterized in that: The nucleic acid modification induced by tobacco toxic compounds is used as a detection marker, and the regulatory effect of the candidate drug on the nucleic acid modification level is quantitatively analyzed by LC-MS / MS.
6. The screening method according to claim 5, characterized in that The nucleic acid modification marker is selected from 5-HMdC, N 2 -CMdG, 5-FdC, 8-oxo-dG, CrotondG and combinations thereof.
7. A drug composition for detoxifying tobacco, characterized in that: The invention comprises a honeysuckle extract and pharmaceutically acceptable excipients, wherein the content of chlorogenic acid in the honeysuckle extract is not less than 1.5%, the content of caffeic acid is not less than 1%, and the content of luteolin is not less than 0.05%.
8. The pharmaceutical composition according to claim 7, characterized in that Its dosage form is tablet, capsule, oral solution or granule.
9. A method for detecting tobacco exposure, characterized in that: Detection of 5-HMdC, N in biological samples by LC-MS / MS 2 -CMdG, 5-FdC, 8-oxo-dG and CrotondG, and used changes in their levels as biomarkers of tobacco exposure.